Advertisement

European Radiology

, Volume 19, Issue 1, pp 230–235 | Cite as

Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?

  • Nyree Griffin
  • Lee A. Grant
  • Susan J. Freeman
  • Mercedes Jimenez-Linan
  • Laurence H. Berman
  • Helena Earl
  • Ahmed Ashour Ahmed
  • Robin Crawford
  • James Brenton
  • Evis Sala
Urogenital

Abstract

In patients with suspected advanced ovarian carcinoma, a precise histological diagnosis is required before commencing neo-adjuvant chemotherapy. This study aims to determine the diagnostic accuracy and complication rate of percutaneous biopsies performed under ultrasound or computed tomography guidance. Between 2002 to 2007, 60 consecutive image-guided percutaneous biopsies were performed in patients with suspected ovarian cancer. The following variables were recorded: tissue biopsied, imaging technique, experience of operator, biopsy needle gauge, number of passes, complications, and final histology. Forty-seven patients had omental biopsies, 12 pelvic mass biopsies, and 1 para-aortic lymph node biopsy. Thirty-five biopsies were performed under ultrasound, 25 under computed tomography guidance. Biopsy needle gauges ranged from 14–20 swg with two to five passes for each patient. There were no complications. Histology was obtained in 52 (87%) patients. Percutaneous image-guided biopsy of peritoneal disease or pelvic mass is safe with high diagnostic accuracy. The large-gauge biopsy needle is as safe as the small gauge needle, but has the added value of obtaining tissue samples for immunohistochemistry and genomic studies.

Keywords

Ovary Neoplasms Ultrasound Computed tomography Biopsy 

References

  1. 1.
    Walkey MM, Freidman AC, Sohotra AC, Radecki PD (1988) CT manifestations of peritoneal carcinomatosis. AJR 150:1035–1041PubMedGoogle Scholar
  2. 2.
    Griffiths CT (1975) Surgical resection of tumour bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMedGoogle Scholar
  3. 3.
    Pecorelli S, Odicino F, Favalli G (2002) Interval debulking surgery in advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16:573–583PubMedCrossRefGoogle Scholar
  4. 4.
    van der Burg ME, van Lent M, Buyse M et al (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629–634PubMedCrossRefGoogle Scholar
  5. 5.
    Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489–2497PubMedCrossRefGoogle Scholar
  6. 6.
    McCluggage WG, Lyness RW, Atkinson RJ, Dobbs SP, Harley I, McClelland HR, Price JH (2002) Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55:27–31PubMedGoogle Scholar
  7. 7.
    McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumours. Semin Diagn Pathol 22:3–32PubMedCrossRefGoogle Scholar
  8. 8.
    Fehrmann RSN, Li X-y, van der Zee AGJ et al (2007) Profiling studies in ovarian cancer: a review. The Oncologist 12:960–966PubMedCrossRefGoogle Scholar
  9. 9.
    Hewitt MJ, Anderson K, Hall GD et al (2007) Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG 114:46–50PubMedCrossRefGoogle Scholar
  10. 10.
    Spencer JA, Swift SE, Wilkinson N et al (2001) Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care. Radiology 221:173–177PubMedCrossRefGoogle Scholar
  11. 11.
    Pombo F, Rodriguez E, Martin R, Lago M (1997) CT-guided core-needle biopsy in omental pathology. Acta Radiol 38:978–981PubMedGoogle Scholar
  12. 12.
    Earl HM, Ahmed A, Vallier A et al (2006) Cambridge Translational Cancer Research Ovarian Study 01 (CTCR-OV01): Expression profiling of advanced epithelial ovarian cancer (EOC) to predict chemotherapy response. A randomised phase II trial design with prospective translational endpoints. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement):15018Google Scholar
  13. 13.
    Stewart CJR, Coldewey J, Stewart IS (2002) Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol 55:93–97PubMedGoogle Scholar
  14. 14.
    Layfield LJ, Gopez EV (2003) Percutaneous image-guided fine-needle aspiration of peritoneal lesions. Diagn Cytopathol 28:6–12PubMedCrossRefGoogle Scholar
  15. 15.
    Yeow KM, Tsay PK, Cheung YC, Lui KW, Pan KT, Chou AS (2003) Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle lung biopsy: retrospective analysis of 631 procedures. J Vasc Interv Radiol 14:581–8PubMedGoogle Scholar
  16. 16.
    Spentzos D, Levine DA, Ramoni MF et al (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700–4710PubMedCrossRefGoogle Scholar
  17. 17.
    Berchuck A, Iversen Es, Lancaster JM et al (2005) Patterns of gene expression that characterize long term survival in advanced stage serous ovarian cancer. Clin Cancer Res 11:3686–3696PubMedCrossRefGoogle Scholar
  18. 18.
    Harmann LC, Lu KH, Linette GP et al (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11:2149–2155CrossRefGoogle Scholar
  19. 19.
    Spentzos D, Levin DA, Kolia S et al (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23:7911–7918PubMedCrossRefGoogle Scholar
  20. 20.
    Helleman J, Jansen MP, Span PN et al (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118:1963–1971PubMedCrossRefGoogle Scholar
  21. 21.
    Crijns APG, te Meeman GJ, Fehrmann RSN et al (2006) Gene expression profile associated with response to chemotherapy in advanced stage ovarian cancer. Presented at 97th AACR Annual meeting, Washington DC April 1–5 2006Google Scholar
  22. 22.
    Dressman HJ, Berchuck A, Chan G et al (2007) An integrated genomic-based approach to individualised treatment of patients with advanced stage ovarian cancer. J Clin Oncol 25:517–525PubMedCrossRefGoogle Scholar
  23. 23.
    Karoo RO, Lloyd TD, Garcea G, Redway HD, Robertson GS (2003) How valuable is ascitic cytology in the detection and management of malignancy? Postgrad Med J 79:292–294PubMedCrossRefGoogle Scholar
  24. 24.
    J Moss EL, Hollingworth J, Reynolds TM (2005) The role of CA125 in clinical practice. Clin. Pathol 58:308–312CrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2008

Authors and Affiliations

  • Nyree Griffin
    • 1
  • Lee A. Grant
    • 1
  • Susan J. Freeman
    • 1
  • Mercedes Jimenez-Linan
    • 3
  • Laurence H. Berman
    • 1
  • Helena Earl
    • 2
  • Ahmed Ashour Ahmed
    • 2
  • Robin Crawford
    • 2
  • James Brenton
    • 2
  • Evis Sala
    • 1
  1. 1.Department of RadiologyAddenbrooke’s HospitalCambridgeUK
  2. 2.Department of OncologyAddenbrooke’s HospitalCambridgeUK
  3. 3.Department of HistopathologyAddenbrooke’s HospitalCambridgeUK

Personalised recommendations